# nuvigtherapeutics.com

> AI-optimized mirror of nuvigtherapeutics.com containing 18 pages totalling 13,087 words of clean markdown content, structured data, and semantic HTML. Original source: https://nuvigtherapeutics.com. Last updated: 2026-07-26T05:04:39.733Z.

Each page is available as HTML (with JSON-LD structured data) and Markdown (text-only, ideal for LLMs and RAG).

## Homepage

- [Novel Therapies for Chronic Autoimmune Diseases | Nuvig Therapeutics](/content/site-root.html): Our mission is to bring innovative and transformational therapies to patients with chronic autoimmune disease, via induction of mechanisms that restore immune homeostasis. (203 words)

## Articles & Blog Posts

- [Privacy Policy | Nuvig Therapeutics](/content/nuvigtx-com/privacy-policy/index.html): Last updated June 2, 2026 Thank you for choosing to be part of our community at Nuvig Therapeutics, Inc., (“company”, “we”, “us”, or “our”). We are committed to protecting your personal information and your right to privacy. If you have any questions or concerns about our policy, or our practices with regards to your personal... (3,627 words)
- [nuvigtx-com/wp-content/uploads/2024/08/nuvig-keystone-abstract-may-2024-pdf.html](/content/nuvigtx-com/wp-content/uploads/2024/08/nuvig-keystone-abstract-may-2024-pdf.html) (386 words)
- [Nuvig Therapeutics | Our Science](/content/nuvigtx-com/science/index.html): NVG-2089 triggers our bodies’ endogenous regulatory mechanisms to reduce autoimmune dysregulation without immunosuppression. (457 words)
- [Terms of Use | Nuvig Therapeutics](/content/nuvigtx-com/terms-of-use/index.html): Effective Date: May 1, 2022 Last Updated: May 1, 2022 The following Terms of Use Agreement (“Agreement”) govern and apply to your use and/or reliance upon this website. PLEASE READ AND REVIEW THIS AGREEMENT CAREFULLY EVERY TIME YOU ACCESS OR USE THE WEBSITE. BY ACCESSING OR USING THE WEBSITE, YOU ACKNOWLEDGE THAT YOU HAVE READ,... (1,173 words)
- [Nuvig Therapeutics | Pipeline](/content/nuvigtx-com/pipeline/index.html): We aim to bring safe, efficacious immune-modulating therapies to patients with autoimmune disease. (514 words)
- [Nuvig Therapeutics | Cookie Policy](/content/nuvigtx-com/cookie-policy/index.html) (816 words)
- [Careers to Transform Medicine | Nuvig Therapeutics](/content/nuvigtx-com/careers/index.html): Our goal is to fundamentally transform the way we think about and treat inflammatory and autoimmune diseases. (654 words)
- [Nuvig News | Novel Therapies for Chronic Autoimmune Diseases](/content/nuvigtx-com/news/index.html): Learn more about how Nuvig is translating novel scientific insights into therapies for inflammatory and autoimmune diseases. (142 words)
- [Nuvig Therapeutics Appoints Celia J.F. Lin, M.D., as Chief Medical Officer | Nuvig Therapeutics](/content/nuvigtx-com/nuvig-therapeutics-appoints-celia-j-f-lin-m-d-as-chief-medical-officer.html): Dr. Lin joins Nuvig to advance NVG-2089 through Phase 2 studies in chronic inflammatory demyelinating polyneuropathy and immune thrombocytopenia and shape the next wave of immunomodulating therapies from the company’s BESTech™ platform Palo Alto, Calif., Nuvig Therapeutics, Inc., (“Nuvig”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, today... (706 words, Nov 18, 2025)
- [Nuvig Therapeutics Appoints David J. Woodhouse, Ph.D., as Chief Executive Officer and James Mackay, Ph.D., as Independent Board Chair | Nuvig Therapeutics](/content/nuvigtx-com/nuvig-therapeutics-appoints-david-j-woodhouse-ph-d-as-chief-executive-officer-and-james-mackay-ph-d-as-independent-board-chair.html): Menlo Park, Calif., September 9, 2025 – Nuvig Therapeutics, Inc. (“Nuvig”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, today announced the appointment of David J. Woodhouse, Ph.D., as Chief Executive Officer and member of the Board of Directors and James Mackay, Ph.D., as Independent Board Chair. “David’s... (660 words, Sep 9, 2025)
- [Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data | Nuvig Therapeutics](/content/nuvigtx-com/nuvig-therapeutics-announces-first-patient-dosed-in-phase-2-cidp-trial-of-nvg-2089-and-presentation-of-phase-1-data.html): NVG-2089 is a recombinant Fc fusion protein designed to replicate key immunomodulatory functions of IVIg with greater consistency, scalability, and patient convenience Phase 1 data show NVG-2089 was well tolerated with no serious or severe adverse events, supporting advancement into Phase 2 development for CIDP Menlo Park, Calif., May 14, 2025 – Nuvig Therapeutics, Inc.,... (733 words, May 14, 2025)
- [Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator | Nuvig Therapeutics](/content/nuvigtx-com/nuvig-therapeutics-announces-161-million-series-b-financing-and-progression-to-phase-2-development-with-novel-second-generation-immunomodulator.html): Menlo Park, Calif., December 5, 2024 – Nuvig Therapeutics, Inc., (“Nuvig”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, announced today the closing of a $161 million Series B financing. The financing was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture... (815 words, Dec 5, 2024)
- [Nuvig Initiates Clinical Development of Next-Generation Immune Modulator NVG-2089 | Nuvig Therapeutics](/content/nuvigtx-com/nuvig-initiates-clinical-development-of-next-generation-immune-modulator-nvg-2089.html): Redwood City, Calif., February 12, 2024 – Nuvig Therapeutics, Inc., (“Nuvig” or the “Company”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases today announced the first-in-human dosing of NVG-2089, a proprietary product being developed to treat patients with inflammatory myopathies and severe dermatologic autoimmune disease. Nuvig also announced... (339 words, Feb 12, 2024)
- [Nuvig Therapeutics Appoints Dr. Alan Glicklich Chief Medical Officer | Nuvig Therapeutics](/content/nuvigtx-com/nuvig-therapeutics-appoints-dr-alan-glicklich-chief-medical-officer.html): Physician and biopharmaceutical leadership executive with extensive experience in novel drug development, operations management, and team building Redwood City, Calif., October 4, 2023 – Nuvig Therapeutics, Inc., a private biotech company developing novel biologic therapeutics to treat inflammatory autoimmune diseases, announced today the appointment of Alan Glicklich, M.D., as Chief Medical Officer. Dr. Glicklich has... (434 words, Oct 4, 2023)
- [Nuvig Launches to Develop Novel Immune Therapeutics for Chronic Inflammatory and Autoimmune Diseases | Nuvig Therapeutics](/content/nuvigtx-com/nuvig-launches-to-develop-novel-immune-therapeutics-for-chronic-inflammatory-and-autoimmune-diseases.html): Redwood City, Calif., May 11, 2022 – Nuvig Therapeutics, Inc., announced today the launch of the company to develop novel therapeutics that induce mechanisms of immune homeostasis and treat autoimmune diseases without compromising normal immune function. To support this mission, the company has closed a $47 million Series A financing, led by Novo Holdings A/S... (622 words, May 11, 2022)

## About Pages

- [Team | Nuvig Therapeutics](/content/nuvigtx-com/team/index.html): We are an experienced and accomplished scientific and development team who have filed multiple investigational new drug applications (INDs) (736 words)
- [Nuvig Contact | Novel Therapies for Chronic Autoimmune Diseases](/content/nuvigtx-com/contact/index.html): Contact Nuvig to learn more about new therapies in development for chronic inflammatory and autoimmune diseases. (70 words)

## Resources

- [Full Page Index](/index.html): Browse all cached pages with rich metadata
- [About This Cache](/content/about.html): Methodology, technical details, and usage guidelines
- [XML Sitemap](/sitemap.xml): Machine-readable sitemap for crawler discovery
- [Robots.txt](/robots.txt): Crawler directives